Your browser is no longer supported. Please, upgrade your browser.
UTHR United Therapeutics Corporation weekly Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Index- P/E9.24 EPS (ttm)12.96 Insider Own0.10% Shs Outstand45.63M Perf Week-2.47%
Market Cap5.46B Forward P/E9.66 EPS next Y12.40 Insider Trans-85.27% Shs Float44.97M Perf Month-13.45%
Income662.90M PEG0.43 EPS next Q2.70 Inst Own- Short Float17.47% Perf Quarter-23.81%
Sales1.41B P/S3.88 EPS this Y91.50% Inst Trans2.12% Short Ratio12.89 Perf Half Y-27.50%
Book/sh32.49 P/B3.69 EPS next Y-6.57% ROA34.50% Target Price172.50 Perf Year-18.37%
Cash/sh20.20 P/C5.93 EPS next 5Y21.57% ROE54.00% 52W Range113.20 - 190.29 Perf YTD-23.54%
Dividend- P/FCF12.78 EPS past 5Y79.20% ROI25.40% 52W High-36.37% Beta1.72
Dividend %- Quick Ratio2.10 Sales past 5Y29.10% Gross Margin95.80% 52W Low6.96% ATR6.50
Employees740 Current Ratio2.20 Sales Q/Q17.00% Oper. Margin51.40% RSI (14)36.06 Volatility5.47% 5.45%
OptionableYes Debt/Eq0.02 EPS Q/Q- Profit Margin47.10% Rel Volume1.06 Prev Close119.74
ShortableYes LT Debt/Eq0.00 EarningsFeb 23 BMO Payout0.00% Avg Volume609.24K Price121.08
Recom2.20 SMA20-3.57% SMA50-15.33% SMA200-22.26% Volume418,537 Change1.12%
Feb-10-16Upgrade Standpoint Research Hold → Buy $148
Jul-31-15Reiterated Argus Buy $205 → $200
Jul-29-15Reiterated RBC Capital Mkts Sector Perform $160 → $175
May-27-15Reiterated Argus Buy $195 → $205
Apr-29-15Reiterated RBC Capital Mkts Sector Perform $135 → $160
Mar-12-15Upgrade Argus Hold → Buy $195
Mar-04-15Downgrade Standpoint Research Buy → Hold
Feb-26-15Reiterated H.C. Wainwright Buy $150 → $175
Nov-03-14Downgrade Argus Buy → Hold
Oct-15-14Upgrade Standpoint Research Hold → Buy $144
Aug-29-14Reiterated Standpoint Research Buy $118 → $140
Jul-30-14Reiterated H.C. Wainwright Buy $120 → $150
Apr-07-14Upgrade Standpoint Research Hold → Buy $118
Feb-26-14Reiterated RBC Capital Mkts Sector Perform $80 → $90
Feb-26-14Reiterated Ladenburg Thalmann Buy $138 → $135
Dec-31-13Reiterated Argus Buy $120 → $130
Dec-23-13Upgrade Ladenburg Thalmann Neutral → Buy $138
Dec-02-13Reiterated Argus Buy $85 → $110
Aug-05-13Reiterated Argus Buy $75 → $85
Jul-30-13Downgrade Standpoint Research Buy → Hold
Feb-10-16 12:49PM  United Therapeutics upgraded by Standpoint Research
Feb-03-16 09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, United Therapeutics and INSYS Therapeutics
Feb-02-16 10:46AM  4 Top-Ranked Biotech Stocks on Sale
Feb-01-16 06:13AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material De
Jan-19-16 03:22PM  United Therapeutics settles patent dispute with Teva Pharmaceuticals at bizjournals.com
09:30AM  The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals
06:05AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Other Events
Jan-07-16 04:50PM  Cardiome/SteadyMed's PAH Drug Approved for Review in EU
Jan-06-16 11:24AM  United Therapeutics Corp. Value Analysis (NASDAQ:UTHR) : January 6, 2016
08:11AM  United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : January 6, 2016
06:00AM  United Therapeutics Corporation To Present At 34th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-31-15 12:44PM  Rockville biotech preps for trials after getting rare pediatric drug status at bizjournals.com
Dec-28-15 07:13PM  New IBD 50 Tech Stocks: LinkedIn Not The Only Network at Investor's Business Daily
Dec-23-15 09:09AM  8 Biotech Stocks That Should Be in Your Portfolio Right Now at TheStreet
Dec-08-15 01:16PM  UNITED THERAPEUTICS CORP Financials
11:45AM  Moogfest headliners announced for 2016 Durham debut at bizjournals.com
Dec-07-15 07:00AM  SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin GlobeNewswire
Dec-01-15 04:03PM  Top Stock Picks of Multi-Billion Dollar, Healthcare-Focused Fund Palo Alto Investors at Insider Monkey
10:31AM  Hedge Funds Are Selling YPF SA (ADR) (YPF) at Insider Monkey
Nov-24-15 11:03AM  How Smart Money Is Trading United Therapeutics Corporation (UTHR) at Insider Monkey
Nov-21-15 03:03PM  United Therapeutics' Stock Picked Up Steam in October: Time to Buy? at Motley Fool
Nov-11-15 06:04AM  United Therapeutics Stock: What is the Social Media Crowd Thinking About UTHR? -5.16%
Nov-06-15 10:17AM  An Overview of QUALs Holdings
Nov-02-15 05:00PM  United Therapeutics Led the Biotechnology Subgroup for the Week
12:58AM  Drug Makers Buy Pricey Vouchers to Speed Products to Market at The Wall Street Journal
Nov-01-15 08:31PM  Drug Makers Buy Pricey Vouchers to Speed Products to Market at The Wall Street Journal
Oct-30-15 09:44AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : October 30, 2015
Oct-28-15 12:18PM  United Therapeutics Beats on Q3 Earnings, Revenues
08:45AM  United Therapeutics (UTHR) Catches Eye: Stock Jumps 8.8%
Oct-27-15 04:23PM  Edited Transcript of UTHR earnings conference call or presentation 27-Oct-15 1:00pm GMT +8.78%
07:07AM  Q3 2015 United Therapeutics Corp Earnings Release - Before Market Open
06:15AM  United Therapeutics tops Street 3Q forecasts
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report
06:00AM  United Therapeutics Corporation Reports Third Quarter 2015 Financial Results PR Newswire
Oct-21-15 07:00AM  SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent GlobeNewswire
06:00AM  United Therapeutics Corporation To Announce Third Quarter 2015 Financial Results Before Market Open On Tuesday, October 27, 2015 PR Newswire
Oct-20-15 01:16PM  Drug companies are paying huge sums to fast-track FDA approval at Fortune
Oct-15-15 05:34PM  Winnebago, United Therapeutics Lead Payout Hikes at Investor's Business Daily
06:07AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
06:00AM  United Therapeutics Announces Additional $500 Million Share Repurchase Program PR Newswire
Oct-02-15 05:20AM  What LinkedIn can tell us about filling open jobs (Video) at bizjournals.com
Oct-01-15 11:04AM  United Therapeutics Corp. Earnings Q2, 2015
Sep-30-15 06:08AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
06:00AM  United Therapeutics Announces Settlement of Patent Litigation with Sandoz Inc. PR Newswire
Sep-29-15 11:25AM  Independent Research Sees 3 Top Health and Biotech Stocks as Oversold at 24/7 Wall St.
Sep-25-15 10:06AM  Alnylam and United Therapeutics: Worst Performers of Mid-Cap
Sep-24-15 05:02PM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets
Sep-22-15 04:30PM  Synthetic Genomics Inc. Expands Collaborative Research and Development Agreement with Lung Biotechnology PBC, a Subsidiary of United Therapeutics Corporation, to Develop Organs for Transplantation PR Newswire
11:06AM  IBB Mid-Cap Outperforms XBI Mid-Cap
Sep-11-15 04:57PM  United Therapeutics Corporation's Stock Slumped in August: Is It Now a Bargain? at Motley Fool
Sep-02-15 01:15PM  Chip, Biotech ETFs, Gutted In August, Lead Relief Rally at Investor's Business Daily +6.32%
Aug-27-15 12:55PM  CEO pay surged last year after stock-market gains, pension changes at MarketWatch
Aug-20-15 04:35PM  United Therapeutics to Sell Priority Review Voucher to AbbVie
12:09AM  Investors Should Review AbbVie Deal as a Priority at The Wall Street Journal
Aug-19-15 07:06PM  Investors Should Review AbbVie Deal as a Priority at The Wall Street Journal
02:55PM  How Duke Fuqua profs connect to a $350M pharma transaction at bizjournals.com
10:41AM  AbbVie buys special review voucher for $350 mln Reuters
06:45AM  United Therapeutics Sells Priority-Review Voucher to AbbVie at The Wall Street Journal
06:05AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure
06:00AM  United Therapeutics Corporation Agrees to Sell Priority Review Voucher to AbbVie for $350 Million PR Newswire
Aug-17-15 06:00AM  European Commission Grants Marketing Authorisation for Unituxin (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma PR Newswire
Aug-06-15 06:00AM  United Therapeutics Corporation To Present At The 2015 Wedbush PacGrow Healthcare Conference PR Newswire
Jul-29-15 12:35PM  United Therapeutics Misses on Q2 Earnings & Revenues - Analyst Blog
Jul-28-15 04:42PM  United Therapeutics (UTHR) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
04:09PM  4 IBD 50 Stocks Poised To Bounce Back With Market
01:34PM  Edited Transcript of UTHR earnings conference call or presentation 28-Jul-15 1:00pm GMT
01:13PM  5 Health Care Stocks to Trade for Gains -- Must-See Charts at TheStreet
11:01AM  United Therapeutics Plunges On Q2 Sales Miss at Investor's Business Daily
07:07AM  Q2 2015 United Therapeutics Corp Earnings Release - Before Market Open
06:16AM  United Therapeutics beats 2Q profit forecasts
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report
06:00AM  United Therapeutics Corporation Reports Second Quarter 2015 Financial Results PR Newswire
Jul-25-15 10:02AM  Meet 5 IBD 50 Stocks Reporting Earnings This Week at Investor's Business Daily
Jul-22-15 06:00AM  United Therapeutics Corporation To Announce Second Quarter 2015 Financial Results Before Market Open On Tuesday, July 28, 2015 PR Newswire
Jul-21-15 12:24PM  Why This Analyst Expects New Alzhemiers Trials Could Produce the Most Important Drugs in History
Jul-18-15 01:10AM  Biotech: The Forgotten Bubble at Barrons.com
Jun-29-15 03:53PM  Why Jazz Pharmaceuticals Is Winning
06:06AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc
06:00AM  Dean Judy D. Olian Joins the United Therapeutics Corporation Board of Directors PR Newswire
Jun-26-15 04:11PM  This entrepreneur wants to fix the transplant shortage by recycling human organs
Jun-24-15 02:52PM  Dow Slips Back Below 18,000; GM Plunges; Autohome Up at Investor's Business Daily
Jun-22-15 06:28PM  IBD Market Wrap - 06/22/15
Jun-18-15 03:02PM  Jacksonville lung transplant center will be the first of its kind in the U.S., bringing more jobs and capital investment at bizjournals.com
09:10AM  KYTH up 26.7% over past day, pushes Palo Alto Investors Forward
Jun-17-15 03:00PM  Silver Spring biotech faces patent challenge for major revenue drug at bizjournals.com
12:01PM  Bioscience firm planning major expansion in Silver Spring at bizjournals.com
Jun-16-15 04:55PM  United Therapeutics Faces Patent Challenge for Tyvaso - Analyst Blog
Jun-15-15 04:25PM  UTHR CEO: Future of biotech
09:16AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
09:00AM  United Therapeutics Corporation Receives Paragraph IV Notice Letter for Tyvaso PR Newswire
Jun-01-15 04:00PM  United Therapeutics Corporation - ZER Reports
May-29-15 06:00AM  United Therapeutics Corporation To Present At The Jefferies 2015 Global Healthcare Conference PR Newswire
May-20-15 06:00AM  Jim Cramer's Top Takeaways: United Therapeutics, American Airlines, Wix.com at TheStreet
May-19-15 07:58PM  Jim Cramer's 'Mad Money' Recap: Looking for Profitable Retailers? Follow the Clues at TheStreet
07:26PM  Cramer Remix: It went to $500 from $5 & isn't done at CNBC
06:46PM  Highest paid female CEO: Race to save my daughter at CNBC
May-05-15 01:40PM  Apple's Angela Ahrendts Is Nation's Best-Paid Female Executive
May-04-15 05:43PM  Live forever? Maybe, by uploading your brain at CNBC
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE AChairman & Co-CEOFeb 04Option Exercise30.755,547170,5705,787Feb 08 08:09 AM
MAHON PAUL AEVP & General CounselFeb 04Option Exercise49.826,000298,92141,054Feb 08 04:48 PM
CAUSEY CHRISTOPHERDirectorFeb 04Option Exercise51.7775038,8281,708Feb 08 04:49 PM
DWEK RAYMONDDirectorFeb 04Option Exercise41.143,000123,4203,000Feb 04 04:21 PM
ROTHBLATT MARTINE AChairman & Co-CEOFeb 04Sale122.135,547677,459240Feb 08 08:09 AM
DWEK RAYMONDDirectorFeb 04Sale122.663,000367,9860Feb 04 04:21 PM
JEFFS ROGERPresident & Co-CEOJan 27Option Exercise65.803,000197,4003,559Jan 28 05:03 PM
JEFFS ROGERPresident & Co-CEOJan 22Option Exercise65.803,000197,4003,559Jan 26 04:12 PM
MAHON PAUL AEVP & General CounselJan 21Option Exercise47.506,000285,00041,054Jan 22 07:48 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 21Option Exercise30.755,547170,5705,787Jan 22 07:48 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 21Sale127.005,547704,444240Jan 22 07:48 PM
JEFFS ROGERPresident & Co-CEOJan 20Option Exercise65.803,000197,4003,559Jan 21 04:26 PM
JEFFS ROGERPresident & Co-CEOJan 15Option Exercise65.803,000197,4003,559Jan 20 07:08 AM
ROTHBLATT MARTINE AChairman & Co-CEOJan 14Option Exercise30.755,546170,5405,786Jan 19 12:16 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 14Sale135.945,546753,900240Jan 19 12:16 PM
JEFFS ROGERPresident & Co-CEOJan 13Option Exercise65.803,000197,4003,559Jan 14 04:51 PM
JEFFS ROGERPresident & Co-CEOJan 08Option Exercise65.804,000263,2004,559Jan 11 04:32 PM
DWEK RAYMONDDirectorJan 07Option Exercise41.143,000123,4203,000Jan 07 04:51 PM
PATUSKY CHRISTOPHERDirectorJan 07Option Exercise48.113,000144,3303,000Jan 08 04:43 PM
CAUSEY CHRISTOPHERDirectorJan 07Option Exercise49.332,250110,9932,458Jan 08 04:44 PM
MAHON PAUL AEVP & General CounselJan 07Option Exercise47.506,000285,00041,054Jan 08 04:44 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 07Option Exercise30.755,547170,5705,787Jan 08 04:46 PM
DWEK RAYMONDDirectorJan 07Sale143.753,000431,2550Jan 07 04:51 PM
ROTHBLATT MARTINE AChairman & Co-CEOJan 07Sale145.845,547808,973240Jan 08 04:46 PM
JEFFS ROGERPresident & Co-CEOJan 06Option Exercise65.804,000263,2004,559Jan 07 04:53 PM
JEFFS ROGERPresident & Co-CEOJan 04Option Exercise65.805,000329,0005,559Jan 05 04:44 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 31Option Exercise30.755,546170,5405,786Jan 04 04:15 PM
JEFFS ROGERPresident & Co-CEODec 30Option Exercise65.805,000329,0005,559Dec 31 12:00 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerDec 29Option Exercise65.802,000131,6003,375Dec 30 04:02 PM
JEFFS ROGERPresident & Co-CEODec 28Option Exercise65.805,000329,0005,559Dec 30 04:03 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 24Option Exercise30.755,546170,5405,786Dec 28 04:37 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 24Sale159.585,546885,030240Dec 28 04:37 PM
JEFFS ROGERPresident & Co-CEODec 23Option Exercise65.805,000329,0005,559Dec 28 08:01 AM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerDec 22Option Exercise65.802,000131,6003,375Dec 23 04:05 PM
JEFFS ROGERPresident & Co-CEODec 18Option Exercise65.805,000329,0005,559Dec 21 04:07 PM
MAHON PAUL AEVP & General CounselDec 17Option Exercise47.506,000285,00041,054Dec 21 04:07 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 17Option Exercise30.755,546170,5405,786Dec 18 04:22 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 17Sale158.495,546878,982240Dec 18 04:22 PM
JEFFS ROGERPresident & Co-CEODec 16Option Exercise65.805,000329,0005,559Dec 17 04:04 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerDec 15Option Exercise65.802,000131,6003,375Dec 16 04:49 PM
JEFFS ROGERPresident & Co-CEODec 11Option Exercise65.804,000263,2004,559Dec 14 04:07 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 10Option Exercise30.755,546170,5405,786Dec 11 04:03 PM
ROTHBLATT MARTINE AChairman & Co-CEODec 10Sale154.495,546856,825240Dec 11 04:03 PM
JEFFS ROGERPresident & Co-CEODec 09Option Exercise65.804,000263,2004,559Dec 10 04:42 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerDec 08Option Exercise65.802,000131,6003,375Dec 10 04:43 PM
JEFFS ROGERPresident & Co-CEODec 04Option Exercise65.805,000329,0005,559Dec 08 03:05 PM
DWEK RAYMONDDirectorDec 03Option Exercise41.143,000123,4203,000Dec 03 04:10 PM
CAUSEY CHRISTOPHERDirectorDec 03Option Exercise48.111,50072,1652,458Dec 04 04:20 PM
MAHON PAUL AEVP & General CounselDec 03Option Exercise47.506,000285,00041,054Dec 04 04:21 PM
DWEK RAYMONDDirectorDec 03Sale157.223,000471,6700Dec 03 04:10 PM
JEFFS ROGERPresident & Co-CEODec 02Option Exercise65.805,000329,0005,559Dec 03 04:11 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerDec 01Option Exercise65.802,000131,6003,375Dec 02 04:07 PM
JEFFS ROGERPresident & Co-CEONov 27Option Exercise65.804,000263,2004,559Nov 30 04:15 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 27Option Exercise30.765,561171,0585,786Nov 30 04:14 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 27Sale153.815,561855,340240Nov 30 04:14 PM
JEFFS ROGERPresident & Co-CEONov 25Option Exercise64.385,000321,8904,059Nov 30 04:15 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerNov 24Option Exercise63.432,000126,8602,375Nov 25 02:34 PM
JEFFS ROGERPresident & Co-CEONov 20Option Exercise61.064,000244,2404,559Nov 24 04:02 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 19Option Exercise32.379,661312,7545,786Nov 20 04:09 PM
MAHON PAUL AEVP & General CounselNov 19Option Exercise47.506,000285,00041,054Nov 20 04:41 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 19Sale148.569,6611,435,267240Nov 20 04:09 PM
JEFFS ROGERPresident & Co-CEONov 18Option Exercise61.064,000244,2404,559Nov 20 04:10 PM
JEFFS ROGERPresident & Co-CEONov 13Option Exercise61.064,000244,2404,559Nov 17 08:03 AM
ROTHBLATT MARTINE AChairman & Co-CEONov 12Option Exercise30.755,546170,5405,786Nov 13 04:05 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 12Option Exercise34.564,115142,2144,355Nov 12 04:03 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 12Sale147.125,546815,903240Nov 13 04:05 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 12Sale147.724,115607,885240Nov 12 04:03 PM
JEFFS ROGERPresident & Co-CEONov 11Option Exercise61.064,000244,2404,559Nov 12 04:04 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerNov 10Option Exercise61.062,000122,1203,375Nov 12 04:05 PM
JEFFS ROGERPresident & Co-CEONov 06Option Exercise61.064,000244,2404,559Nov 09 04:25 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 05Option Exercise30.755,546170,5405,786Nov 09 04:26 PM
PATUSKY CHRISTOPHERDirectorNov 05Option Exercise41.145,000205,7005,000Nov 09 04:28 PM
MAHON PAUL AEVP & General CounselNov 05Option Exercise47.506,000285,00041,054Nov 09 04:27 PM
CAUSEY CHRISTOPHERDirectorNov 05Option Exercise48.111,50072,1652,458Nov 09 04:29 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 05Option Exercise34.564,115142,2144,355Nov 06 04:28 PM
DWEK RAYMONDDirectorNov 05Option Exercise41.143,000123,4203,000Nov 06 04:33 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 05Sale150.215,546833,038240Nov 09 04:26 PM
ROTHBLATT MARTINE AChairman & Co-CEONov 05Sale149.164,115613,802240Nov 06 04:28 PM
DWEK RAYMONDDirectorNov 05Sale149.633,000448,8840Nov 06 04:33 PM
JEFFS ROGERPresident & Co-CEONov 04Option Exercise61.064,000244,2404,559Nov 06 04:33 PM
ZACCARDELLI DAVIDEVP & Chief Operating OfficerNov 03Option Exercise61.062,000122,1203,375Nov 04 04:21 PM
Giltner RichardDirectorNov 03Option Exercise31.047,500232,7637,500Nov 04 04:22 PM
Giltner RichardDirectorNov 03Sale153.227,5001,149,1720Nov 04 04:22 PM
JEFFS ROGERPresident & Co-CEOOct 30Option Exercise61.064,000244,2404,559Nov 02 04:17 PM
CAUSEY CHRISTOPHERDirectorOct 29Option Exercise48.111,50072,1652,458Oct 30 04:04 PM
ROTHBLATT MARTINE AChairman & Co-CEOOct 29Option Exercise32.379,662312,7855,787Oct 30 04:26 PM
ROTHBLATT MARTINE AChairman & Co-CEOOct 29Sale141.899,6621,370,916240Oct 30 04:26 PM
ROTHBLATT MARTINE AChairman & Co-CEOOct 28Option Exercise63.222,211139,7792,451Oct 30 04:28 PM
JEFFS ROGERPresident & Co-CEOOct 28Option Exercise61.0612,000732,72012,559Oct 30 04:27 PM
ROTHBLATT MARTINE AChairman & Co-CEOOct 28Sale136.582,211301,976240Oct 30 04:28 PM
JEFFS ROGERPresident & Co-CEOOct 27Option Exercise57.152,500142,8753,059Oct 28 04:01 PM
ROTHBLATT MARTINE AChairman & Co-CEOOct 26Option Exercise52.652,592136,4692,832Oct 27 04:55 PM
ROTHBLATT MARTINE AChairman & Co-CEOOct 26Sale127.132,592329,529240Oct 27 04:55 PM
JEFFS ROGERPresident & Co-CEOOct 23Option Exercise61.063,000183,1803,559Oct 26 04:04 PM
ROTHBLATT MARTINE AChairman & Co-CEOOct 22Option Exercise32.379,662312,7855,787Oct 23 04:21 PM
ROTHBLATT MARTINE AChairman & Co-CEOOct 22Sale122.409,6621,182,615240Oct 23 04:21 PM
ROTHBLATT MARTINE AChairman & Co-CEOOct 21Option Exercise63.222,211139,7792,451Oct 22 03:59 PM
ROTHBLATT MARTINE AChairman & Co-CEOOct 21Sale123.632,211273,339240Oct 22 03:59 PM
JEFFS ROGERPresident & Co-CEOOct 16Option Exercise61.066,000366,3606,559Oct 19 04:16 PM
MAHON PAUL AEVP & General CounselOct 15Option Exercise47.506,000285,00041,054Oct 19 06:46 AM